Randomized controlled trialHumanClinical Trial, Phase III
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
The New England journal of medicine, 2025 Aug 14. Garvey WT, Blüher M, Osorto Contreras CK and 9 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2025 Aug 14
PubMed
Where PepCue cites this
This paper is part of the evidence base behind these profiles. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultAgedFemaleHumansMaleMiddle AgedAnti-Obesity AgentsBody Mass IndexDouble-Blind MethodObesityOverweightWeight Loss
Other papers on Cagrilintide
Randomized controlled trial · 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Journal article · 2025Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page